These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12543651)

  • 1. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.
    Pastore C; Picchio GR; Galimi F; Fish R; Hartley O; Offord RE; Mosier DE
    Antimicrob Agents Chemother; 2003 Feb; 47(2):509-17. PubMed ID: 12543651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.
    Mosier DE; Picchio GR; Gulizia RJ; Sabbe R; Poignard P; Picard L; Offord RE; Thompson DA; Wilken J
    J Virol; 1999 May; 73(5):3544-50. PubMed ID: 10196243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression.
    Sabbe R; Picchio GR; Pastore C; Chaloin O; Hartley O; Offord R; Mosier DE
    J Virol; 2001 Jan; 75(2):661-71. PubMed ID: 11134280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.
    Kawamura T; Bruse SE; Abraha A; Sugaya M; Hartley O; Offord RE; Arts EJ; Zimmerman PA; Blauvelt A
    J Virol; 2004 Jul; 78(14):7602-9. PubMed ID: 15220435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.
    Lobritz MA; Ratcliff AN; Marozsan AJ; Dudley DM; Tilton JC; Arts EJ
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2640-50. PubMed ID: 23529732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity.
    Mack M; Luckow B; Nelson PJ; Cihak J; Simmons G; Clapham PR; Signoret N; Marsh M; Stangassinger M; Borlat F; Wells TN; Schlöndorff D; Proudfoot AE
    J Exp Med; 1998 Apr; 187(8):1215-24. PubMed ID: 9547333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
    Torre VS; Marozsan AJ; Albright JL; Collins KR; Hartley O; Offord RE; Quiñones-Mateu ME; Arts EJ
    J Virol; 2000 May; 74(10):4868-76. PubMed ID: 10775626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.
    Jin J; Colin P; Staropoli I; Lima-Fernandes E; Ferret C; Demir A; Rogée S; Hartley O; Randriamampita C; Scott MG; Marullo S; Sauvonnet N; Arenzana-Seisdedos F; Lagane B; Brelot A
    J Biol Chem; 2014 Jul; 289(27):19042-52. PubMed ID: 24855645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.
    Marozsan AJ; Torre VS; Johnson M; Ball SC; Cross JV; Templeton DJ; Quiñones-Mateu ME; Offord RE; Arts EJ
    J Virol; 2001 Sep; 75(18):8624-38. PubMed ID: 11507208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of chemokine-mediated block to HIV entry with coreceptor internalization.
    Brandt SM; Mariani R; Holland AU; Hope TJ; Landau NR
    J Biol Chem; 2002 May; 277(19):17291-9. PubMed ID: 11782464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocytosis and recycling of the HIV coreceptor CCR5.
    Signoret N; Pelchen-Matthews A; Mack M; Proudfoot AE; Marsh M
    J Cell Biol; 2000 Dec; 151(6):1281-94. PubMed ID: 11121442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.
    Gaertner H; Cerini F; Escola JM; Kuenzi G; Melotti A; Offord R; Rossitto-Borlat I; Nedellec R; Salkowitz J; Gorochov G; Mosier D; Hartley O
    Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17706-11. PubMed ID: 19004761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation.
    Polo S; Nardese V; De Santis C; Arcelloni C; Paroni R; Sironi F; Verani A; Rizzi M; Bolognesi M; Lusso P
    Eur J Immunol; 2000 Nov; 30(11):3190-8. PubMed ID: 11093134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
    Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
    J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.
    Aquaro S; Menten P; Struyf S; Proost P; Van Damme J; De Clercq E; Schols D
    J Virol; 2001 May; 75(9):4402-6. PubMed ID: 11287590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines.
    Hartley O; Dorgham K; Perez-Bercoff D; Cerini F; Heimann A; Gaertner H; Offord RE; Pancino G; Debré P; Gorochov G
    J Virol; 2003 Jun; 77(12):6637-44. PubMed ID: 12767983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.
    Maeda Y; Foda M; Matsushita S; Harada S
    J Virol; 2000 Feb; 74(4):1787-93. PubMed ID: 10644351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion.
    Gordon CJ; Muesing MA; Proudfoot AE; Power CA; Moore JP; Trkola A
    J Virol; 1999 Jan; 73(1):684-94. PubMed ID: 9847374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.